Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

HER2 Intermediate Breast Cancers.

Jensen KC, Nielsen TO, Gilks CB, West RB.

Am J Surg Pathol. 2009 Nov;33(11):1739; author reply 1739-40. doi: 10.1097/PAS.0b013e3181b72865. No abstract available.

PMID:
19745698
2.

Accuracy and precision in HER2/neu testing in breast cancer: are we there yet?

Yaziji H, Gown AM.

Hum Pathol. 2004 Feb;35(2):143-6. No abstract available.

PMID:
14991529
3.

[Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor].

Fernö M, Haglund M, Bendahl PO, Olsson H, Rydén L.

Lakartidningen. 2008 Aug 6-19;105(32-33):2181-4. Swedish. No abstract available.

PMID:
18780693
4.

HER2 testing recommendations in Australia.

Bilous M; HER2 Testing Advisory Board.

Pathology. 2001 Nov;33(4):425-7. Review.

PMID:
11827407
5.

New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody.

Sakamoto G, Mitsuyama S.

Breast Cancer. 2000;7(4):350-7. No abstract available.

PMID:
11114864
6.

HER2 testing and correlation with efficacy of trastuzumab therapy.

Fornier M, Risio M, Van Poznak C, Seidman A.

Oncology (Williston Park). 2002 Oct;16(10):1340-8, 1351-2; discussion 1352, 1355-8. Review.

7.

HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.

O'Malley FP, Thomson T, Julian J, Have C, Cosby R, Gelmon K, Andrulis I, Whelan T.

Arch Pathol Lab Med. 2008 Jan;132(1):61-5. doi: 10.1043/1543-2165(2008)132[61:HTIAPS]2.0.CO;2. Erratum in: Arch Pathol Lab Med.2008 May;132(5):730. Crosby, Roxanne [corrected to Cosby, Roxanne].

PMID:
18181675
8.

How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.

Schmidt C.

J Natl Cancer Inst. 2011 Jan 19;103(2):87-9. doi: 10.1093/jnci/djq557. Epub 2010 Dec 29. No abstract available.

PMID:
21191114
9.

Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.

Ross JS.

Drug News Perspect. 2009 Mar;22(2):93-106. doi: 10.1358/dnp.2009.22.2.1334452. Review.

PMID:
19330168
10.

[Assessment of HER2 status in breast cancer].

Penault-Llorca F, Cayre A.

Bull Cancer. 2004 Dec 1;91 Suppl 4:S211-5. Review. French.

11.

Saving lives with accurate HER2 testing.

Ross JS.

Am J Clin Pathol. 2010 Aug;134(2):183-4. doi: 10.1309/AJCP6VZ8YHMZNNED. No abstract available.

PMID:
20660318
12.

Inconsistency of HER2 test raises questions.

Tuma RS.

J Natl Cancer Inst. 2007 Jul 18;99(14):1064-5. Epub 2007 Jul 10. No abstract available.

PMID:
17623788
13.

Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab).

Umemura S, Sakamoto G, Sasano H, Tsuda H, Akiyama F, Kurosumi M, Tokuda Y, Watanabe T, Toi M, Hasegawa T, Osamura RY.

Breast Cancer. 2001;8(4):316-20. Review.

PMID:
11791124
14.

Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.

Blank PR, Schwenkglenks M, Moch H, Szucs TD.

Breast Cancer Res Treat. 2010 Nov;124(2):497-507. doi: 10.1007/s10549-010-0862-7. Epub 2010 Apr 3.

PMID:
20364309
15.

[HER-2 diagnostics].

Bánkfalvi A.

Magy Onkol. 2002;46(1):11-5. Epub 2003 Feb 3. Review. Hungarian.

16.

Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.

Chang HJ, Han SW, Oh DY, Im SA, Jeon YK, Park IA, Han W, Noh DY, Bang YJ, Kim TY.

Jpn J Clin Oncol. 2011 May;41(5):593-9. doi: 10.1093/jjco/hyr020. Epub 2011 Mar 15.

PMID:
21406492
17.

[Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].

Lehr HA, Schaefer SC, Delaloye JF.

Rev Med Suisse. 2009 Jul 15;5(211):1525-9. French.

PMID:
19694364
18.

Re: HER2 testing in the real world.

Vincent-Salomon A, MacGrogan G, Couturier J, Arnould L, Mathoulin-Pélissier S; Groupe d'Etude des Facteurs Pronostiques par Immunohistochime dans les Cancers du Sein.

J Natl Cancer Inst. 2003 Apr 16;95(8):628; author reply 628-9. No abstract available.

PMID:
12697858
19.

HER2 status in a population-derived breast cancer cohort: discordances during tumor progression.

Wilking U, Karlsson E, Skoog L, Hatschek T, Lidbrink E, Elmberger G, Johansson H, Lindström L, Bergh J.

Breast Cancer Res Treat. 2011 Jan;125(2):553-61. doi: 10.1007/s10549-010-1029-2. Epub 2010 Jul 14.

PMID:
20628810
20.

Trastuzumab administration associated with change in HER2 status.

Dawood S, Resetkova E, Gonzalez-Angulo AM.

Clin Breast Cancer. 2008 Aug;8(4):366-9. doi: 10.3816/CBC.2008.n.044.

PMID:
18757266

Supplemental Content

Support Center